raloxifene hydrochloride has been researched along with Kidney Diseases in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Jamdade, VS; Li, H | 1 |
| Ali, RAH; Altimimi, M; Hadi, NR | 1 |
| Jamdade, VS; Kumar, P; Lahkar, M; Mundhe, NA; Tadla, V | 1 |
| Hamano, T | 1 |
| Braga, S; Cannata-Andía, JB; Carrillo-López, N; Fernández-Coto, T; López-Hernández, F; Lopez-Novoa, JM; Naves-Díaz, M; Rodríguez-Rodríguez, A | 1 |
| Ishimura, E; Okuno, S | 1 |
| Czock, D; Heringa, M; Keller, F; Rasche, FM | 1 |
2 review(s) available for raloxifene hydrochloride and Kidney Diseases
| Article | Year |
|---|---|
[Effects of SERMs on bone health. The potential of SERM in the care of chronic kidney disease-mineral bone and disorders].
Topics: Bone Density Conservation Agents; Bone Diseases, Metabolic; Chronic Disease; Evidence-Based Medicine; Fractures, Spontaneous; Humans; Kidney Diseases; Osteoporosis; Parathyroid Hormone; Practice Guidelines as Topic; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Vitamin D | 2010 |
[Secondary osteoporosis UPDATE. Bone disease with decreased kidney function].
Topics: Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Chronic Disease; Diphosphonates; Fractures, Spontaneous; Humans; Kidney Diseases; Minerals; Raloxifene Hydrochloride; Reference Standards | 2010 |
1 trial(s) available for raloxifene hydrochloride and Kidney Diseases
| Article | Year |
|---|---|
Raloxifene pharmacokinetics in males with normal and impaired renal function.
Topics: Adult; Area Under Curve; Creatinine; Half-Life; Humans; Kidney; Kidney Diseases; Male; Middle Aged; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2005 |
4 other study(ies) available for raloxifene hydrochloride and Kidney Diseases
| Article | Year |
|---|---|
Raloxifene impedes cisplatin-induced nephrotoxicity through inhibition of Proinflammatory cytokines in female wistar rats.
Topics: Animals; Anti-Inflammatory Agents; Blood Urea Nitrogen; Cisplatin; Creatinine; Cytokines; Disease Models, Animal; Female; Inflammation Mediators; Kidney; Kidney Diseases; Raloxifene Hydrochloride; Rats, Wistar | 2021 |
The potential renoprotective effect of Raloxifene in renal ischemia-reperfusion injury in a male rat model.
Topics: Animals; Antioxidants; Caspase 3; Creatinine; Ischemia; Kidney; Kidney Diseases; Male; Oxidative Stress; Raloxifene Hydrochloride; Rats; Reactive Oxygen Species; Reperfusion Injury; Tumor Necrosis Factor-alpha; Urea | 2023 |
Raloxifene Inhibits NF-kB Pathway and Potentiates Anti-Tumour Activity of Cisplatin with Simultaneous Reduction in its Nephrotoxictiy.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Cisplatin; Drug Synergism; Female; Inflammation; Kidney Diseases; Mammary Neoplasms, Animal; NF-kappa B; Raloxifene Hydrochloride; Rats; Rats, Wistar; Signal Transduction | 2016 |
Differential effects of 17beta-estradiol and raloxifene on bone and lipid metabolism in rats with chronic kidney disease and estrogen insufficiency.
Topics: Animals; Atrophy; Bone Density Conservation Agents; Calcitriol; Calcium; Cholesterol; Chronic Disease; Estradiol; Estrogens; Female; Hyperplasia; Kidney Diseases; Mammary Glands, Animal; Organ Size; Parathyroid Hormone; Phosphorus; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Selective Estrogen Receptor Modulators; Tibia; Uterus | 2010 |